DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company specializing in food allergies and immunologic treatments, has announced the filing of its 2025 Half-Year Report with the French market authority (AMF) for the period ending June 30, 2025.
The report is available in French on the company's website under the Investors/Financial Information section, on the AMF website, and can be requested directly from DBV Technologies via mail or email.
DBV Technologies (NASDAQ:DBVT), un'azienda biofarmaceutica in fase clinica specializzata in allergie alimentari e trattamenti immunologici, ha annunciato la presentazione del Rapporto Semestrale 2025 all'autorità di mercato francese (AMF) per il periodo conclusosi il 30 giugno 2025.
Il rapporto è disponibile in francese sul sito web dell'azienda nella sezione Investitori/Informazioni Finanziarie, sul sito dell'AMF e può essere richiesto direttamente a DBV Technologies via posta o email.
DBV Technologies (NASDAQ:DBVT), una compañía biofarmacéutica en etapa clínica especializada en alergias alimentarias y tratamientos inmunológicos, ha anunciado la presentación de su Informe Semestral 2025 ante la autoridad de mercado francesa (AMF) para el período que finaliza el 30 de junio de 2025.
El informe está disponible en francés en el sitio web de la empresa, en la sección de Inversores/Información Financiera, en el sitio web de la AMF, y puede solicitarse directamente a DBV Technologies por correo postal o electrónico.
DBV Technologies (NASDAQ:DBVT)는 식품 알레르기 및 면역 치료를 전문으로 하는 임상 단계 바이오제약 회사로, 2025년 6월 30일 종료된 기간에 대한 2025년 반기 보고서를 프랑스 시장 당국(AMF)에 제출했다고 발표했습니다.
해당 보고서는 회사 웹사이트의 투자자/재무 정보 섹션과 AMF 웹사이트에서 프랑스어로 제공되며, DBV Technologies에 우편 또는 이메일로 직접 요청할 수도 있습니다.
DBV Technologies (NASDAQ:DBVT), une société biopharmaceutique en phase clinique spécialisée dans les allergies alimentaires et les traitements immunologiques, a annoncé le dépôt de son rapport semestriel 2025 auprès de l'autorité des marchés financiers française (AMF) pour la période se terminant le 30 juin 2025.
Le rapport est disponible en français sur le site internet de la société dans la section Investisseurs/Informations financières, sur le site de l'AMF, et peut être demandé directement auprès de DBV Technologies par courrier postal ou électronique.
DBV Technologies (NASDAQ:DBVT), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Nahrungsmittelallergien und immunologische Behandlungen spezialisiert hat, hat die Einreichung seines Halbjahresberichts 2025 bei der französischen Marktaufsichtsbehörde (AMF) für den Zeitraum bis zum 30. Juni 2025 bekannt gegeben.
Der Bericht ist auf Französisch auf der Website des Unternehmens im Bereich Investoren/Finanzinformationen, auf der AMF-Website verfügbar und kann direkt bei DBV Technologies per Post oder E-Mail angefordert werden.
- None.
- None.
Châtillon, France, July 29, 2025
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2025, of its Half-Year Report with the French market authority, “Autorité des Marchés Financiers” (“AMF”).
The 2025 Half-Year Report can be consulted or downloaded from the Company’s website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only.
It is also available free of charge upon request:
- by mail : DBV Technologies – 107 avenue de la République 92320 Châtillon, France ;
- by email: investors@dbv-technologies.com.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
Where can investors access DBV Technologies' (DBVT) 2025 Half-Year Report?
What is the reporting period for DBV Technologies' (DBVT) latest Half-Year Report?
What is DBV Technologies' (DBVT) main business focus?
How can investors request DBV Technologies' (DBVT) 2025 Half-Year Report directly from the company?
